1st Latin American Pharmacogenomics Congress

Day 1:	May 12, 2010
Venue:	UPR Medical Sciences Campus
0900	Welcome - President of the
	UPR/Medical School Chancellor
0910	Welcome – Murray Lumpkin, Deputy
	Commissioner for International
	Programs, U.S. Food and Drug
	Administration
0920	Keynote 1, Allen Roses
1000	Session 1
	SUCCESSES AND CHALLENGES IN
	PHARMACOGENOMICS
	Chair: Larry Lesko
	DIT T.
4020	P1: Larry Lesko
1030	P2: George Patrinos
1100	P3: Howard McLeod
1130	COFFEE BREAK
1200	P4: Federico Innocenti
1230	P5: Luis Parodi
1300	P6: Felix Frueh
1330	LUNCH
1430	Session 2
1450	POPULATION GENOMICS
	STUDIES
	Chair: Gualberto Ruaño
4.500	P7: Jorge Duconge (Puerto Rico)
1500	P8: Irma Silva (México)
1530	P9: Andrés Ruiz Linares (Colombia)
1600	P10: Guilherme Suarez-Kurtz (Brazil)
1630	P11: Esteban Parra (South America)
1700	END OF DAY 1
1900	Reception Cocktail at Courtyard Executive Director of PRIDCO
1930	DINNER

1st Latin American Pharmacogenomics Congress

Day 2:	May 13, 2010
Venue:	FDA Campus
venue.	FDA Campus
0000	W. M. CHE D. D.
0900	Welcome - Maridalia Torres, Puerto
	Rico District Director, FDA
0915	Session 3
	REGULATORY ISSUES IN
	PHARMACOGENOMICS
	Chair: Issam Zineh
	Chair Casant Eliter
	P12: Michael Pacanowski (FDA)
0945	P13: Marisa Papaluca (EMA)
1015	P14: Gyselle Saddi Tannous (Brazil)
40.45	COEPEE PPE LV
1045	COFFEE BREAK
4400	
1100	Session 4
	INFRASTRUCTURE FOR
	DEVELOPMENT OF
	PHARMACOGENOMICS
	Chair: Federico Goodsaid
	P15: Federico Goodsaid
1130	P16: Rick Hockett
1200	P17: Alex Parker
1200	11/1/IIICA I di lici
1230	LUNCH
1250	Borten
1330	P18: David Logan
1400	P19: Gualberto Ruaño
1400	F19: Guaiderto Kuano
1430	Session 5
1450	CASE STUDIES IN LATIN
	AMERICAN
	PHARMACOGENOMICS I.
	Chair: Alfredo Hidalgo
	P20: Alfredo Hidalgo (México)
1500	P21: Esteban Burchard (US)
1530	P22: Adrián Llerena (Spain)
1600	END OF DAY 2
1900	DINNER at Platos
	(http://www.platosrestaurant.com)

1st Latin American Pharmacogenomics Congress

Day 3:	May 14, 2010
Venue:	AMGEN Campus
0900	Welcome – Emilio Rivera, VP of
	Amgen Operations in Puerto Rico
0915	Session 6
	CASE STUDIES IN LATIN
	AMERICAN
	PHARMACOGENOMICS II.
	Chair: Guilherme Suarez-Kurtz
	P23: Guilherme Suarez-Kurtz (Brazil)
0945	P24: Mara Helena Hutz (Brazil)
1015	P25: Diadelis Remírez (Cuba)
4045	COPER ADD IV
1045	COFFEE BREAK
1100	Session 7
	PHARMACOGENOMIC
	BIOMARKERS IN THE
	PHARMACEUTICAL INDUSTRY
	Chair: Scott Patterson
	P26: Scott Patterson
1130	P27: Sally John
1200	P28: Sandy Close
1230	LUNCH
1330	Session 8
1550	PAYING FOR
	PHARMACOGENOMICS
	Chair: Felix Frueh
4400	P29: Carlos Iribarren
1400	P30: Francisco Joglar Pesquera
1430 1500	P31: MAPFRE PANEL ON PAYING FOR
1300	PHARMACOGENOMICS
1530	AMGEN Tour
1630	Keynote 2, Howard McLeod
1700	MEETING SUMMARY AND
	CONCLUSIONS

Day 1: May 12, 2010













TIME	SPEAKER	TITLE TO THE STATE OF THE STATE	
0900 0910	The state of the s		
920	K1, Allen Roses	A PGX-assisted Alzheimer's Disease "delay of onset" clinical trial: simultaneous validation of a new diagnostic and phylogenetic implications for admixture in clinical studies	
1000	Session 1 Chair: Larry Lesko	SUCCESSES AND CHALLENGES IN PHARMACOGENOMICS	
1030 1100	P1: Larry Lesko P2: George Patrinos P3: Howard McLeod	Application of pharmacogenomics for hemoglobinopathies therapeutics Efficacy pharmacogenetics: lessons from tamoxifen	
1130	COFFEE BREAK		
1200 1230 1300	P4: Federico Innocenti P5: Luis Parodi P6: Felix Frueh	Multivariate gene expression profiles: an effective approach to develop clinically useful diagnostics	
1330	LUNCH		
1430	Session 2 Chair: Gualberto Ruaño	POPULATION GENOMICS STUDIES	
1500 1530	P7: Jorge Duconge (Puerto Rico) P8: Irma Silva P9: Andrés Ruiz Linares (Colombia)	Admixture in the Puerto Rican population: physiogenomic analysis and implications for personalized medicine Genomic diversity of Mexican mestizo and Amerindian groups	
1600 1630	P10: Guilherme Suarez-Kurtz P11: Esteban Parra	Pharmacogenomic implications of genetic admixture in Brazilians. Genome-wide studies in admixed populations: challenges and opportunities	
1700	END OF DAY 1		
1900	Reception Cocktail Executive Director of PRIDCO		
1930	DINNER		

Day 2: May 13, 2010 Venue: FDA Campus











TIME	SPEAKER	TITLI
------	---------	-------

0900 Welcome - Maridalia Torres, Puerto Rico District Director, FDA

0915 Session 3 REGULATORY ISSUES IN PHARMACOGENOMICS

Chair: Issam Zineh

P12: Michael Pacanowski Translational pharmacogenomics: the FDA experience

0945 P13: Marisa Papaluca (EMA)

1015 P14: Gyselle Saddi Tannous (Brazil)

1045 COFFEE BREAK

1100 Session 4 INFRASTRUCTURE FOR DEVELOPMENT OF PHARMACOGENOMICS

Chair: Federico Goodsaid

P15: Federico Goodsaid Ways and means in the development of pharmacogenomics

1130 P16: Rick Hockett

1200 P17: Alex Parker Applications of next-generation sequencing to pharmacogenomics

1230 LUNCH

1330 P18: David Logan Delivering the value of personalized medicine to physicians, patients and payors

1400 P19: Gualberto Ruaño DNA-guided medicine in healthcare today: business case studies in mental health and cardiovascular markets

1430 Session 5 CASE STUDIES IN LATIN AMERICAN PHARMACOGENOMICS I.

Chair: Alfredo Hidalgo

P20: Alfredo Hidalgo High-throughput analysis of genetic diversity in ADME related genes in the

Mexican population: PGENI Mexico.

1500 P21: Esteban Burchard Scientific Advantages of Genetic Studies in Racially Admixed Populations: Lessons from the Genetics of Asthma

in Latino Americans (GALA) Study

1530 P22: Adrián Llerena CYP2D6 pheno-and genotyping in Iberoamerican populations

1600 END OF DAY 2

1900 DINNER

Day 3: May 14, 2010
Venue: AMGEN Campus











SPEAKER		
Welcome – Emilio Rivera, VP of Amgen Operations in Puerto Rico		
Session 6 Chair: Guilherme Suarez-Kurtz	CASE STUDIES IN LATIN AMERICAN PHARMACOGENOMICS II.	
P23: Guilherme Suarez-Kurtz P24: Mara Helena Hutz P25: Diadelis Remírez	Pharmacogenetic studies in Brazilians: anticoagulants and HIV-protease inhibitors Pharmacogenomics of Attention-Deficit/Hyperactivity Disorder Pharmacogenetic studies: results and regulatory perspectives in Cuba	
COFFEE BREAK		
Session 7 Chair: Scott Patterson	PHARMACOGENOMIC BIOMARKERS IN THE PHARMACEUTICAL INDUSTRY	
P26: Scott Patterson P27: Sally John P28: Sandy Close	KRAS as a negative selection pharmacogenomic biomarker: The Path to Clinical Usefulness The international Serious Adverse Events Consortium: Unraveling the genetic basis of drug induced liver injury Pharmacogenetics of Thienopyridines	
LUNCH		
Session 8 Chair: Felix Frueh	PAYING FOR PHARMACOGENOMICS	
P29: Carlos Iribarren P30: Francisco Joglar Pesquera P31: Edgardo J. Silva-Jimenéz Chair, P29, P30 and P31	Kaiser process for integration of genetic testing into evidence-based guidelines SSS Statistics for pharmacogenetic testing in Puerto Rico PANEL ON PAYING FOR PHARMACOGENOMICS	
AMGEN Tour		
K2: Howard McLeod	Pharmacogenetics as a public health tool	
ALL	MEETING SUMMARY AND CONCLUSIONS	
	Session 6 Chair: Guilherme Suarez-Kurtz P23: Guilherme Suarez-Kurtz P24: Mara Helena Hutz P25: Diadelis Remírez COFFEE BREAK Session 7 Chair: Scott Patterson P26: Scott Patterson P27: Sally John P28: Sandy Close LUNCH Session 8 Chair: Felix Frueh P29: Carlos Iribarren P30: Francisco Joglar Pesquera P31: Edgardo J. Silva-Jimenéz Chair, P29, P30 and P31 AMGEN Tour K2: Howard McLeod	